Search

Your search keyword '"Pariente, Jérémie"' showing total 539 results

Search Constraints

Start Over You searched for: Author "Pariente, Jérémie" Remove constraint Author: "Pariente, Jérémie"
539 results on '"Pariente, Jérémie"'

Search Results

202. Additional file 2: of Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man

203. Additional file 2: of Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man

205. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients

206. Huntington's Disease with Small CAG Repeat Expansions.

207. Can neurodevelopmental disorders influence the course of neurodegenerative diseases? A scoping review.

208. Exploring the impact of the interthalamic adhesion on human cognition: insights from healthy subjects and thalamic stroke patients.

209. Prevalence and characteristics of vascular cognitive impairment in a European cohort of adult patients with Moyamoya angiopathy.

210. Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort.

211. Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update.

212. Taking the A Train? Limited Consistency of Aβ42 and the Aβ42/40 Ratio in the AT(N) Classification.

213. Language Network Connectivity Increases in Early Alzheimer's Disease.

214. The long-term impact of irradiation on functional connectivity in brain circuits involved in memory processes after pediatric posterior fossa tumor.

215. Increased functional connectivity supports language performance in healthy aging despite gray matter loss.

216. Post-stroke remodeling processes in animal models and humans.

217. Grey Matter changes in treatment-resistant depression during electroconvulsive therapy.

218. Enlarged perivascular spaces and florbetapir uptake in patients with intracerebral hemorrhage.

219. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial

220. Neuronal spiking activity highlights a gradient of epileptogenicity in human tuberous sclerosis lesions.

221. The Regulatory Role of the Human Mediodorsal Thalamus.

223. Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression.

224. Alteration of rhythmic unimanual tapping and anti-phase bimanual coordination in Alzheimer's disease: A sign of inter-hemispheric disconnection?

225. Familiarity and recollection vs representational models of medial temporal lobe structures: A single-case study.

226. Memory scrutinized through electrical brain stimulation: A review of 80 years of experiential phenomena.

228. Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Nonamyloid Logopenic Variant

229. The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire

230. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects.

231. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification.

232. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial

233. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience.

234. Clinical manifestations of intermediate allele carriers in Huntington disease

235. Errata

236. Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.

237. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

238. MRI hypoperfusion as a determinant of cognitive impairment in adults with Moyamoya angiopathy.

239. Translocator protein (TSPO) genotype does not change cerebrospinal fluid levels of glial activation, axonal and synaptic damage markers in early Alzheimer's disease.

240. Assessment of Mendelian and risk-factor genes in Alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening.

241. Disfluency patterns in Alzheimer's disease and frontotemporal lobar degeneration.

242. Robust thalamic nuclei segmentation from T1-weighted MRI using polynomial intensity transformation.

243. Effects of sociodemographic and player characteristics on baseline cognitive performance in 1000 rugby players: A retrospective 8-year follow-up study.

244. Physical activity, biomarkers of brain pathologies and dementia risk: Results from the Memento clinical cohort.

245. Expressive Prosody in Patients With Focal Anterior Temporal Neurodegeneration.

246. Clinical heterogeneity of neuro-inflammatory PET profiles in early Alzheimer's disease.

247. Longitudinal head-to-head comparison of 11 C-PiB and 18 F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.

248. [Neurological forms of long COVID in adults: Critical approach].

249. Impact of a pediatric posterior fossa tumor and its treatments on motor procedural learning.

250. Cerebrospinal fluid YKL-40 level evolution is associated with autoimmune encephalitis remission.

Catalog

Books, media, physical & digital resources